Hexarelin 5mg

Hexarelin (also known as Examorelin, developmental codes EP-23905 and MF-6003) is a synthetic, peptidic, and potent agonist of the ghrelin/growth hormone secretagogue receptor (GHSR-1a). It is a hexapeptide that was developed by Mediolanum Farmaceutici. While primarily known for its powerful ability to stimulate the release of growth hormone (GH) from the pituitary gland, independently and synergistically with Growth Hormone-Releasing Hormone (GHRH), research has revealed that Hexarelin also exerts direct, growth hormone-independent effects, particularly on cardiovascular function. These GH-independent effects are often mediated through binding to the CD36 receptor, especially in the heart. Hexarelin reached Phase II clinical trials for growth hormone deficiency and congestive heart failure but was not ultimately marketed.